{"id":11659,"date":"2026-10-28T13:48:58","date_gmt":"2026-10-28T10:48:58","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?ism_drug=mexiletine-meksiletin"},"modified":"2026-10-28T13:48:58","modified_gmt":"2026-10-28T10:48:58","slug":"mexiletine-meksiletin","status":"publish","type":"ism_drug","link":"https:\/\/www.ortaakarsu.net\/?ism_drug=mexiletine-meksiletin","title":{"rendered":"Mexiletine (Meksiletin)"},"content":{"rendered":"<p><strong>Mexiletine (Meksiletin)<\/strong>, Meksiletin etken maddesinin uluslararas\u0131 ad\u0131 \u00fczerinden haz\u0131rlanm\u0131\u015f bilgi sayfas\u0131d\u0131r.<\/p>\n<p><strong>Uygulama kapsam\u0131:<\/strong> A\u011f\u0131zdan, yeterli s\u0131v\u0131 ve yemekle veya \u00fcr\u00fcn talimat\u0131ndaki antasitle al\u0131n\u0131r. Uzam\u0131\u015f ventrik\u00fcler ta\u015fikardide ba\u015flang\u0131\u00e7 hastanede yap\u0131l\u0131r; ki\u015fisel kullan\u0131m ve de\u011fi\u015fiklikleri kardiyoloji ekibi belirler. Farkl\u0131 g\u00fc\u00e7 ve farmas\u00f6tik formlar\u0131n birbirinin yerine kullan\u0131labilece\u011fi varsay\u0131lmamal\u0131d\u0131r.<\/p>\n<h2>T\u00fcrkiye\u2019de yurt d\u0131\u015f\u0131ndan temin kayd\u0131<\/h2>\n<p><a href=\"https:\/\/www.teb.org.tr\/docs\/3aac322e-7bec-4df1-a37f-0dd1757bed11\/yurtdisi-aktif-ilac-listesi\" rel=\"noopener\">TEB\u2019in 2 Ekim 2026 tarihli \u00fcr\u00fcn listesinde<\/a> bu etken maddeyi i\u00e7eren \u00fcr\u00fcn kay\u0131tlar\u0131 do\u011fruland\u0131: MEXILETINE HYDROCHLORIDE CAPSULES USP, 200 MG; TEVA-MEXILETINE HCL 200 MG 100 KAPS\u00dcL. <a href=\"https:\/\/www.titck.gov.tr\/dinamikmodul\/126\" rel=\"noopener\">T\u0130TCK\u2019nin 28 Eyl\u00fcl 2026 tarihli etken madde listesi<\/a> ayr\u0131ca kontrol edildi. Temin ko\u015fullar\u0131 hastaya, re\u00e7eteye, endikasyona ve gerekli onaylara g\u00f6re de\u011fi\u015febilir; listede yer almak g\u00fcncel stok veya geri \u00f6deme garantisi de\u011fildir. Klinik kullan\u0131m alan\u0131 a\u015fa\u011f\u0131daki \u00fcr\u00fcn belgesine g\u00f6re a\u00e7\u0131klan\u0131r; temin listesindeki tan\u0131 ko\u015fullar\u0131 tek ba\u015f\u0131na yeni bir klinik endikasyon olu\u015fturmaz.<\/p>\n<h2>Kaynaklar<\/h2>\n<ul>\n<li><a href=\"https:\/\/pdf.hres.ca\/dpd_pm\/00073596.PDF\" rel=\"noopener\">TEVA-MEXILETINE Kanada \u00fcr\u00fcn monograf\u0131<\/a> (TEVA-MEXILETINE Kanada \u00fcr\u00fcn monograf\u0131; 27.11.2023)<\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11240973\/\" rel=\"noopener\">Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men<\/a> \u2014 Kusumoto M; Ueno K; Oda A; Takeda K; Mashimo K; Takaya K; Fujimura Y; Nishihori T; Tanaka K; Clinical Pharmacology and Therapeutics; 2001; DOI: 10.1067\/mcp.2001.113182<\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10945315\/\" rel=\"noopener\">Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings<\/a> (Labb\u00e9 ve ark., Clin Pharmacol Ther. 2000;68:44\u201357. PMID 10945315; DOI 10.1067\/mcp.2000.108023)<\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1914365\/\" rel=\"noopener\">Mexiletine effects on theophylline disposition<\/a> (Hurwitz ve ark., Clin Pharmacol Ther. 1991;50:299\u2013307. PMID 1914365; DOI 10.1038\/clpt.1991.140)<\/li>\n<\/ul>\n<p>Kaynak kontrol\u00fc: <time datetime=\"2026-10-28\">28 Ekim 2026<\/time>. Bu tarih, bir hekim veya eczac\u0131 taraf\u0131ndan klinik inceleme yap\u0131ld\u0131\u011f\u0131 anlam\u0131na gelmez. Ki\u015fisel tedavi plan\u0131 i\u00e7in kullan\u0131lan \u00fcr\u00fcn\u00fcn g\u00fcncel talimat\u0131 ve sa\u011fl\u0131k uzman\u0131n\u0131n de\u011ferlendirmesi esas al\u0131n\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mexiletine (Meksiletin), Meksiletin etken maddesinin uluslararas\u0131 ad\u0131 \u00fczerinden haz\u0131rlanm\u0131\u015f bilgi  [&#8230;]<\/p>\n","protected":false},"featured_media":0,"template":"","ism_etken_madde":[1280],"class_list":["post-11659","ism_drug","type-ism_drug","status-publish","hentry","ism_etken_madde-meksiletin"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_drug\/11659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_drug"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/ism_drug"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_drug\/11659\/revisions"}],"predecessor-version":[{"id":11660,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_drug\/11659\/revisions\/11660"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11659"}],"wp:term":[{"taxonomy":"ism_etken_madde","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fism_etken_madde&post=11659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}